Synthesis and Biological Evaluation of Two Agents for Imaging Estrogen Receptor β by Positron Emission Tomography: Challenges in PET Imaging of a Low Abundance Target

Overview

Journal Nucl Med Biol

Publisher Elsevier

Specialties Biology
Nuclear Medicine

Date 2012 Jul 4

PMID 22749433

Citations 8

Authors

Jae Hak Lee

Olaf Peters

Lutz Lehmann

Carmen S Dence

Terry L Sharp

Kathryn E Carlson

Dong Zhou

M Jeyakumar

Michael J Welch

John A Katzenellenbogen

Affiliations

Soon will be listed here.

Abstract

Introduction: Independent measurement of the levels of both the estrogen receptors, ERα and ERβ, in breast cancer could improve prediction of benefit from endocrine therapies. While ERα levels can be measured by positron emission tomography (PET) using 16α-[(18)F]fluoroestradiol (FES), no effective agent for imaging ERβ by PET has yet been reported.

Methods: We have prepared the fluorine-18 labeled form of 8β-(2-fluoroethyl)estradiol (8BFEE(2)), an analog of an ERβ-selective steroidal estrogen, 8β-vinylestradiol; efficient incorporation of fluorine-18 was achieved, but required very vigorous conditions. We have examined the biodistribution of this compound, as well as of Br-041, an analog of a known non-steroidal ERβ-selective ligand (ERB-041), labeled with bromine-76. Studies were done in immature female rodents, with various pharmacological and endocrine perturbations to assess ERβ selectivity of uptake.

Results: Little evidence of ERβ-mediated uptake was observed with either [(18)F]8BFEE(2) or [(76)Br]Br-041. Attempts to increase the ERβ content of target tissues were not effective and failed to improve biodistribution selectivity.

Conclusions: Because on an absolute basis level, ERβ levels are low in all target tissues, these studies have highlighted the need to develop improved in vivo models for evaluating ERβ-selective radiopharmaceuticals for use in PET imaging. Genetically engineered breast cancer cells that are being developed to express either ERα or ERβ in a regulated manner, grown as xenografts in immune-compromised mice, could prove useful for future studies to develop ER subtype-selective radiopharmaceuticals.

Citing Articles

FES avid pulmonary adenocarcinoma and confounding ER+ breast carcinoma.

Abdelmoneim Y, Lou Y, Advani P, Khoor A, Sharma A, Parent E Radiol Case Rep. 2024; 20(1):801-804.

PMID: 39624706 PMC: 11609104. DOI: 10.1016/j.radcr.2024.10.114.

Nuclear Receptor Imaging In Vivo-Clinical and Research Advances.

Parent E, Fowler A J Endocr Soc. 2023; 7(3):bvac197.

PMID: 36655003 PMC: 9838808. DOI: 10.1210/jendso/bvac197.

Imaging for illuminating actionable pathways in breast cancer.

Gilardi L, Airo Farulla L, Ceci F Curr Opin Oncol. 2022; 34(6):606-613.

PMID: 36093891 PMC: 10852035. DOI: 10.1097/CCO.0000000000000908.

PET Imaging of Estrogen Receptors Using F-Based Radioligands.

Kumar M, Salem K, Jeffery J, Fowler A Methods Mol Biol. 2022; 2418:129-151.

PMID: 35119664 DOI: 10.1007/978-1-0716-1920-9_9.

Radionuclide-Based Imaging of Breast Cancer: State of the Art.

Li H, Liu Z, Yuan L, Fan K, Zhang Y, Cai W Cancers (Basel). 2021; 13(21).

PMID: 34771622 PMC: 8582396. DOI: 10.3390/cancers13215459.

References

Harris H, Albert L, Leathurby Y, Malamas M, Mewshaw R, Miller C . Evaluation of an estrogen receptor-beta agonist in animal models of human disease. Endocrinology. 2003; 144(10):4241-9. DOI: 10.1210/en.2003-0550. View

Paruthiyil S, Parmar H, Kerekatte V, Cunha G, Firestone G, Leitman D . Estrogen receptor beta inhibits human breast cancer cell proliferation and tumor formation by causing a G2 cell cycle arrest. Cancer Res. 2004; 64(1):423-8. DOI: 10.1158/0008-5472.can-03-2446. View

Mortensen D, Rodriguez A, Carlson K, Sun J, Katzenellenbogen B, Katzenellenbogen J . Synthesis and biological evaluation of a novel series of furans: ligands selective for estrogen receptor alpha. J Med Chem. 2001; 44(23):3838-48. DOI: 10.1021/jm010211u. View

Chang E, Charn T, Park S, Helferich W, Komm B, Katzenellenbogen J . Estrogen Receptors alpha and beta as determinants of gene expression: influence of ligand, dose, and chromatin binding. Mol Endocrinol. 2008; 22(5):1032-43. PMC: 2366177. DOI: 10.1210/me.2007-0356. View

Katzenellenbogen J, JOHNSON Jr H, Myers H . Photoaffinity labels for estrogen binding proteins of rat uterus. Biochemistry. 1973; 12(21):4085-92. DOI: 10.1021/bi00745a010. View

Shanle E, Hawse J, Xu W . Generation of stable reporter breast cancer cell lines for the identification of ER subtype selective ligands. Biochem Pharmacol. 2011; 82(12):1940-9. PMC: 3210412. DOI: 10.1016/j.bcp.2011.08.026. View

McGuire A, Dehdashti F, Siegel B, Lyss A, Brodack J, Mathias C . Positron tomographic assessment of 16 alpha-[18F] fluoro-17 beta-estradiol uptake in metastatic breast carcinoma. J Nucl Med. 1991; 32(8):1526-31. View

Speirs V, Carder P, Lansdown M . Oestrogen receptor beta: how should we measure this?. Br J Cancer. 2002; 87(6):687; author reply 688-9. PMC: 2364250. DOI: 10.1038/sj.bjc.6600534. View

Girault I, Andrieu C, Tozlu S, Spyratos F, Bieche I, Lidereau R . Altered expression pattern of alternatively spliced estrogen receptor beta transcripts in breast carcinoma. Cancer Lett. 2004; 215(1):101-12. DOI: 10.1016/j.canlet.2004.05.006. View

10.

Richardson T, Dodge J, Wang Y, Durbin J, Krishnan V, Norman B . Benzopyrans as selective estrogen receptor beta agonists (SERBAs). Part 5: Combined A- and C-ring structure-activity relationship studies. Bioorg Med Chem Lett. 2007; 17(20):5563-6. DOI: 10.1016/j.bmcl.2007.08.009. View

11.

Chang E, Frasor J, Komm B, Katzenellenbogen B . Impact of estrogen receptor beta on gene networks regulated by estrogen receptor alpha in breast cancer cells. Endocrinology. 2006; 147(10):4831-42. DOI: 10.1210/en.2006-0563. View

12.

Malamas M, Manas E, McDevitt R, Gunawan I, Xu Z, Collini M . Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands. J Med Chem. 2004; 47(21):5021-40. DOI: 10.1021/jm049719y. View

13.

Palmieri C, Cheng G, Saji S, Zelada-Hedman M, Warri A, Weihua Z . Estrogen receptor beta in breast cancer. Endocr Relat Cancer. 2002; 9(1):1-13. DOI: 10.1677/erc.0.0090001. View

14.

Pettersson K, Gustafsson J . Role of estrogen receptor beta in estrogen action. Annu Rev Physiol. 2001; 63:165-92. DOI: 10.1146/annurev.physiol.63.1.165. View

15.

Minutolo F, Macchia M, Katzenellenbogen B, Katzenellenbogen J . Estrogen receptor β ligands: recent advances and biomedical applications. Med Res Rev. 2009; 31(3):364-442. DOI: 10.1002/med.20186. View

16.

Fatum M, Gyo Y, Diana P, Laufer N, Simon A . Is estradiol mandatory for an adequate follicular and embryo development? A mouse model using aromatase inhibitor (anastrozole). J Assist Reprod Genet. 2006; 23(11-12):407-12. PMC: 3455099. DOI: 10.1007/s10815-006-9089-2. View

17.

Seo J, Comninos J, Chi D, Kim D, Carlson K, Katzenellenbogen J . Fluorine-substituted cyclofenil derivatives as estrogen receptor ligands: synthesis and structure-affinity relationship study of potential positron emission tomography agents for imaging estrogen receptors in breast cancer. J Med Chem. 2006; 49(8):2496-511. PMC: 2522267. DOI: 10.1021/jm0512037. View

18.

Carlson K, Choi I, Gee A, Katzenellenbogen B, Katzenellenbogen J . Altered ligand binding properties and enhanced stability of a constitutively active estrogen receptor: evidence that an open pocket conformation is required for ligand interaction. Biochemistry. 1997; 36(48):14897-905. DOI: 10.1021/bi971746l. View

19.

Kim D, Jeong H, Lim S, Sohn M, Katzenellenbogen J, Chi D . Facile nucleophilic fluorination reactions using tert-alcohols as a reaction medium: significantly enhanced reactivity of alkali metal fluorides and improved selectivity. J Org Chem. 2008; 73(3):957-62. DOI: 10.1021/jo7021229. View

20.

Dehdashti F, Mortimer J, Siegel B, Griffeth L, Bonasera T, Fusselman M . Positron tomographic assessment of estrogen receptors in breast cancer: comparison with FDG-PET and in vitro receptor assays. J Nucl Med. 1995; 36(10):1766-74. View